Skip to content
ADVERTISEMENT
Sign In
  • Sections
    • News
    • Advice
    • The Review
  • Topics
    • Data
    • Diversity, Equity, & Inclusion
    • Finance & Operations
    • International
    • Leadership & Governance
    • Teaching & Learning
    • Scholarship & Research
    • Student Success
    • Technology
    • Transitions
    • The Workplace
  • Magazine
    • Current Issue
    • Special Issues
    • Podcast: College Matters from The Chronicle
  • Newsletters
  • Virtual Events
  • Ask Chron
  • Store
    • Featured Products
    • Reports
    • Data
    • Collections
    • Back Issues
  • Jobs
    • Find a Job
    • Post a Job
    • Professional Development
    • Career Resources
    • Virtual Career Fair
  • More
  • Sections
    • News
    • Advice
    • The Review
  • Topics
    • Data
    • Diversity, Equity, & Inclusion
    • Finance & Operations
    • International
    • Leadership & Governance
    • Teaching & Learning
    • Scholarship & Research
    • Student Success
    • Technology
    • Transitions
    • The Workplace
  • Magazine
    • Current Issue
    • Special Issues
    • Podcast: College Matters from The Chronicle
  • Newsletters
  • Virtual Events
  • Ask Chron
  • Store
    • Featured Products
    • Reports
    • Data
    • Collections
    • Back Issues
  • Jobs
    • Find a Job
    • Post a Job
    • Professional Development
    • Career Resources
    • Virtual Career Fair
    Upcoming Events:
    An AI-Driven Work Force
    AI and Microcredentials
Sign In
News

A French Scientist Says He Can Cure Covid-19. Other Researchers Have Their Doubts.

By Tom Bartlett April 1, 2020
Didier Raoult, professor of medicine at Aix-Marseille University
Didier Raoult, professor of medicine at Aix-Marseille UniversityGerard Julien, AFP via Getty Images

Didier Raoult’s résumé speaks for itself. He is among the most highly cited microbiologists in the world. His lab employs a small army of researchers who churn out several hundred papers a year. He has done pioneering work on so-called giant viruses and pathogenic bacteria. A French newspaper once called him “the archetype of the prolific scientist: imaginative, enterprising by nature, persevering, and a bit lucky.”

To continue reading for FREE, please sign in.

Sign In

Or subscribe now to read with unlimited access for as low as $10/month.

Don’t have an account? Sign up now.

A free account provides you access to a limited number of free articles each month, plus newsletters, job postings, salary data, and exclusive store discounts.

Sign Up

Didier Raoult’s résumé speaks for itself. He is among the most highly cited microbiologists in the world. His lab employs a small army of researchers who churn out several hundred papers a year. He has done pioneering work on so-called giant viruses and pathogenic bacteria. A French newspaper once called him “the archetype of the prolific scientist: imaginative, enterprising by nature, persevering, and a bit lucky.”

Other descriptions are less kind. In recent weeks, Raoult, who is a doctor and a professor of medicine at Aix-Marseille University, has been called “Trumpian” and “pathologically resistant to criticism,” while his studies have been dismissed as “misinformation” or simply “crap.”

Raoult and a couple of dozen co-authors have published two observational studies on hydroxychloroquine, an anti-malaria drug that’s already being used by some doctors, including Raoult himself, to treat Covid-19. In their most recent paper, released on March 27, they write that Covid-19 patients given the drug along with azithromycin, an antibiotic, had a reduction in detectable virus. They noted “clinical improvement” in nearly all of the 80 patients tested, with the exception, the researchers note, of a severely ill 86-year-old who died. They write that the results “confirm the efficacy” of the drug combination, and they implore fellow researchers to “urgently evaluate this therapeutic strategy both to avoid the spread of the disease and to treat patients.”

But other researchers are skeptical, and they wasted no time in pointing out why. For starters, the Raoult et al. study was not a randomized clinical trial, which is the gold standard in medical research. That means there was no control group. Other details seemed curious, like the fact that only 15 percent of the patients had fevers, a very common symptom of the disease. As one particularly thorough dissection of the study put it: “We just don’t know how good this treatment was or frankly if it was any good at all.”

You can roll your eyes, but he has done a lot for microbiology. He has discovered a lot of bacteria.

Raoult’s study is just one in a flood of Covid-19-related papers that have appeared in recent weeks, and will continue to be published in coming months as researchers race to understand the disease. Many will turn out to be flawed; some may provide important answers that will lead to treatments to combat the virus. What’s notable about Raoult’s study, and perhaps why it has received outsize attention, is that hydroxychloroquine is the drug that has been seized on by President Trump as a likely cure. Trump called it a “game changer.” Rudy Giuliani, the Trump ally and former New York City mayor, has been playing up hydroxychloroquine on TV and Twitter, and he posted Raoult’s most recent study on his own website, with key passages underlined and a scrawled, semi-legible summary of the findings.

Meanwhile, over the weekend, the Food and Drug Administration issued an emergency authorization that will allow the drug to be used on patients who aren’t in clinical trials. Whether that move was prompted by Trump’s enthusiasm or Raoult’s study, or some other factor, is unclear.

Raoult, who is 68, has been a well-known and respected, if somewhat controversial, figure among microbiologists for decades. A 2012 profile in Science portrays him as influential, cantankerous, and swift to offer a scathing opinion. He calls epidemiologists who model disease outbreaks “charlatans.” It also notes that other scientists complain that his papers, perhaps because they’re published at such a rapid clip, sometimes contain errors. “Raoult says he doesn’t really care what other people think,” the Science article concludes, “and he relishes the constant storm around him.”

Coronavirus seen under electron microscope
Coronavirus Hits Campus
As colleges and universities have struggled to devise policies to respond to the quickly evolving situation, here are links to The Chronicle’s key coverage of how this worldwide health crisis is affecting campuses.
  • Here’s Our List of Colleges’ Reopening Models
  • Fall-Enrollment Trends in Distance Education: a Snapshot
  • Why Is Gettysburg College Giving Up on ‘The Gettysburg Review’?

That’s consistent with his recent attitude toward those who doubt hydroxychloroquine. In late February, he scoffed in a Q&A at those who would question its effectiveness: “When we showed that a drug worked on a hundred people while everyone is having a nervous breakdown, and that there are noodles who say that we are not sure that it works, it does not interest me!” (Raoult did not respond to an email requesting comment for this article.) At the time, he was playing down the danger of what later became a pandemic. Somehow he’s already written a book about Covid-19, and epidemics generally, in which he asserts that “this panic is largely due to the exaggerations of the press, which knows that fear ‘sells.’”

I spoke with Elisabeth Bik about Raoult. Bik is a microbiologist who spends her days ferreting out research misconduct; before that, she spent 15 years working in a Stanford University laboratory. Among Bik and her colleagues, Raoult was considered a major figure in the field. “We didn’t really believe anyone could publish that much,” she says. “You can roll your eyes, but he has done a lot for microbiology. He has discovered a lot of bacteria.”

ADVERTISEMENT

Another microbiologist, Jonathan A. Eisen, a professor at the University of California at Davis, knows Raoult fairly well — Eisen gave a talk not long ago at Raoult’s university, and Raoult introduced him. Eisen describes Raoult in a message as “smart and interesting but also iconoclastic and occasionally out to prove something rather than to study it.”

Bik wrote a post on her blog, Science Integrity Digest, raising questions about Raoult’s most recent hydroxychloroquine study, pointing out that “these were people who — at worst — were only mildly sick.” She emphasized the lack of a control group as the biggest cause for concern. Without that, it’s hard to know whether the drug made any difference at all, considering that the vast majority of patients with Covid-19 recover anyway. As Nick Brown, a researcher also known for exposing flawed and fraudulent research, wrote on Twitter: “They would have gotten the same results with chocolate pudding.”

None of that means hydroxychloroquine isn’t an effective treatment for the coronavirus. It might turn out to be. A new study by researchers based in Wuhan, China, where the outbreak began, showed promising results and, unlike Raoult’s study, included a control group. Meanwhile, researchers at the University of Minnesota-Twin Cities are conducting a clinical trial, also with a control group. Still, scientists who have taken a close look at Raoult’s results have yet to be persuaded that the drug is actually a game-changer.

We welcome your thoughts and questions about this article. Please email the editors or submit a letter for publication.
Tags
Scholarship & Research Innovation & Transformation
Share
  • Twitter
  • LinkedIn
  • Facebook
  • Email
About the Author
Tom Bartlett
Tom Bartlett is a senior writer who covers science and ideas. Follow him on Twitter @tebartl.
ADVERTISEMENT
ADVERTISEMENT

More News

Photo illustration showing Santa Ono seated, places small in the corner of a dark space
'Unrelentingly Sad'
Santa Ono Wanted a Presidency. He Became a Pariah.
Illustration of a rushing crowd carrying HSI letters
Seeking precedent
Funding for Hispanic-Serving Institutions Is Discriminatory and Unconstitutional, Lawsuit Argues
Photo-based illustration of scissors cutting through paper that is a photo of an idyllic liberal arts college campus on one side and money on the other
Finance
Small Colleges Are Banding Together Against a Higher Endowment Tax. This Is Why.
Pano Kanelos, founding president of the U. of Austin.
Q&A
One Year In, What Has ‘the Anti-Harvard’ University Accomplished?

From The Review

Photo- and type-based illustration depicting the acronym AAUP with the second A as the arrow of a compass and facing not north but southeast.
The Review | Essay
The Unraveling of the AAUP
By Matthew W. Finkin
Photo-based illustration of the Capitol building dome propped on a stick attached to a string, like a trap.
The Review | Opinion
Colleges Can’t Trust the Federal Government. What Now?
By Brian Rosenberg
Illustration of an unequal sign in black on a white background
The Review | Essay
What Is Replacing DEI? Racism.
By Richard Amesbury

Upcoming Events

Plain_Acuity_DurableSkills_VF.png
Why Employers Value ‘Durable’ Skills
Warwick_Leadership_Javi.png
University Transformation: a Global Leadership Perspective
  • Explore Content
    • Latest News
    • Newsletters
    • Letters
    • Free Reports and Guides
    • Professional Development
    • Virtual Events
    • Chronicle Store
    • Chronicle Intelligence
    • Jobs in Higher Education
    • Post a Job
  • Know The Chronicle
    • About Us
    • Vision, Mission, Values
    • DEI at The Chronicle
    • Write for Us
    • Work at The Chronicle
    • Our Reporting Process
    • Advertise With Us
    • Brand Studio
    • Accessibility Statement
  • Account and Access
    • Manage Your Account
    • Manage Newsletters
    • Individual Subscriptions
    • Group and Institutional Access
    • Subscription & Account FAQ
  • Get Support
    • Contact Us
    • Reprints & Permissions
    • User Agreement
    • Terms and Conditions
    • Privacy Policy
    • California Privacy Policy
    • Do Not Sell My Personal Information
1255 23rd Street, N.W. Washington, D.C. 20037
© 2025 The Chronicle of Higher Education
The Chronicle of Higher Education is academe’s most trusted resource for independent journalism, career development, and forward-looking intelligence. Our readers lead, teach, learn, and innovate with insights from The Chronicle.
Follow Us
  • twitter
  • instagram
  • youtube
  • facebook
  • linkedin